Hero Banner
Agenda
Saturday, May 20, 2023
Hypertension, Lipids, and Obesity
7:30 AM – 8:30 AM
Breakfast
8:30 AM – 9:00 AM
Break
9:00 AM – 9:05 AM
Day 2 Opening Remarks
Pamela B. Morris, MD
9:05 AM – 9:25 AM
Inflammation and hypertension: novel mechanistic insights
George L. Bakris, MD
9:25 AM – 9:50 AM
Lipoproteins and Inflammation – Focus on LDL, Lp(a) and TG rich lipoproteins and new therapies in development
Christie M. Ballantyne, MD
9:50 AM – 10:15 AM
Obesity, Inflammation and Cardiovascular Risk
Erin D. Michos, MD, MHS, FAHA, FACC, FASE, FASPC
10:15 AM – 11:00 AM
Expert Panel Discussion and Q & A
Moderator: Pamela B. Morris, MD
Panelists: Christie M. Ballantyne, MD; George L. Bakris, MD; Robert H. Eckel, MD; Erin D. Michos, MD, MHS, FAHA, FACC, FASE, FASPC
11:00 AM – 1:00 PM
Break & Exhibit Hall
Type 2 Diabetes and Kidney Disease
1:00 PM
Introductions
Robert H. Eckel, MD
1:00 PM – 1:25 PM
Is there a role of inflammation in type 2 diabetes pathogenesis?
Sam Dagogo-Jack, MD, DSc
1:25 PM – 1:50 PM
CKD, T2DM and inflammation: pathogenesis and more
Jennifer Green, MD
1:50 PM – 2:15 PM
Prevention, screening and treatment of chronic kidney disease
Rajiv Agarwal, MD
2:15 PM – 3:00 PM
Expert Panel Discussion and Q & A
Moderator: Robert H. Eckel, MD
Panelists: Jennifer Green, MD; Rajiv Agarwal, MD; George L. Bakris, MD; Sam Dagogo-Jack, MD, DSc
3:00 PM – 4:30 PM
Break & Exhibit Hall
4:30 PM – 5:30 PM
Dinner
Register Now!

2023 CMHC Spring Registration

$195.00

Gaylord Palms Resort & Convention Center in Orlando

Rate: $379

Deadline: January 16, 2023

Phone: 888-879-0462
(Mention Cardiometabolic Health Congress to get our group rate)

PROSPECTUS

VIEW EXHIBITOR PROSPECTUS  

FAQ's

Here are some common questions we’ll answer NOW, the rest you can ask the experts this May 19-20, 2023, in Orlando!

A: Low-grade systemic inflammation precedes the onset of cardiovascular events by many years, and inflammation is a consistent predictor of cardiovascular risk.

A: A large body of clinical data shows that reducing inflammation has cardiometabolic benefits, and reducing inflammation remains an active area of research that also has important clinical implications, including in the prevention and management of obesity, dyslipidemia, heart failure, chronic kidney disease, hypertension, and type 2 diabetes.

A: An excess of macronutrients in the adipose tissues stimulates inflammatory mediators such as tumor necrosis factor α and interleukin 6; it also reduces the production of adiponectin, promoting inflammation and oxidative stress.

A: Inflammation is a primary mechanism in developed cardiometabolic diseases including coagulation, atherosclerosis, metabolic syndrome, insulin resistance and type 2 diabetes. It is also associated with the development of diseases such as psoriasis, depression, cancer, and renal diseases, conditions that often occur comorbidly in people with cardiometabolic conditions.

A: The activation of nuclear factor kappa B (NF-κB) links pathogenic and cellular danger signals, organizing cellular resistance to perceived threats and triggering inflammation.